Aster DM Healthcare Limited

3.6%

ion Commission of India (“CCI”) for approval of following transaction  Preferential allotment of ~3.6% stake to Blackstone and TPG in the Company (“Preferential Allotment”),  Initial acquisition of 5

5.0%

% stake to Blackstone and TPG in the Company (“Preferential Allotment”),  Initial acquisition of 5.0% stake in Quality Care by the Company (“Initial Acquisition”) and the scheme of amalgamation of Qual

INR 3,138

venue Operating EBITDA1 Op EBITDA Margin Adjusted PAT2 (Post-NCI) 3 RoCE (Pre-Tax) 9MFY25 : INR 3,138 cr 9MFY25 : INR 613 cr 9MFY25 : 19.5% 9MFY25 : INR 251 cr 9MFY25 : 19.5% 15% 35% 288 bps 65%

INR 613

A1 Op EBITDA Margin Adjusted PAT2 (Post-NCI) 3 RoCE (Pre-Tax) 9MFY25 : INR 3,138 cr 9MFY25 : INR 613 cr 9MFY25 : 19.5% 9MFY25 : INR 251 cr 9MFY25 : 19.5% 15% 35% 288 bps 65% 480 bps 9MFY24 : I

19.5%

Adjusted PAT2 (Post-NCI) 3 RoCE (Pre-Tax) 9MFY25 : INR 3,138 cr 9MFY25 : INR 613 cr 9MFY25 : 19.5% 9MFY25 : INR 251 cr 9MFY25 : 19.5% 15% 35% 288 bps 65% 480 bps 9MFY24 : INR 2,721 cr 9MFY2

INR 251

(Post-NCI) 3 RoCE (Pre-Tax) 9MFY25 : INR 3,138 cr 9MFY25 : INR 613 cr 9MFY25 : 19.5% 9MFY25 : INR 251 cr 9MFY25 : 19.5% 15% 35% 288 bps 65% 480 bps 9MFY24 : INR 2,721 cr 9MFY24 : INR 453 cr 9MF

15%

) 9MFY25 : INR 3,138 cr 9MFY25 : INR 613 cr 9MFY25 : 19.5% 9MFY25 : INR 251 cr 9MFY25 : 19.5% 15% 35% 288 bps 65% 480 bps 9MFY24 : INR 2,721 cr 9MFY24 : INR 453 cr 9MFY24 : 16.6% 9MFY24 : I

35%

FY25 : INR 3,138 cr 9MFY25 : INR 613 cr 9MFY25 : 19.5% 9MFY25 : INR 251 cr 9MFY25 : 19.5% 15% 35% 288 bps 65% 480 bps 9MFY24 : INR 2,721 cr 9MFY24 : INR 453 cr 9MFY24 : 16.6% 9MFY24 : INR 15

288 bps

: INR 3,138 cr 9MFY25 : INR 613 cr 9MFY25 : 19.5% 9MFY25 : INR 251 cr 9MFY25 : 19.5% 15% 35% 288 bps 65% 480 bps 9MFY24 : INR 2,721 cr 9MFY24 : INR 453 cr 9MFY24 : 16.6% 9MFY24 : INR 153 cr 9MF

65%

38 cr 9MFY25 : INR 613 cr 9MFY25 : 19.5% 9MFY25 : INR 251 cr 9MFY25 : 19.5% 15% 35% 288 bps 65% 480 bps 9MFY24 : INR 2,721 cr 9MFY24 : INR 453 cr 9MFY24 : 16.6% 9MFY24 : INR 153 cr 9MFY24 :

480 bps

9MFY25 : INR 613 cr 9MFY25 : 19.5% 9MFY25 : INR 251 cr 9MFY25 : 19.5% 15% 35% 288 bps 65% 480 bps 9MFY24 : INR 2,721 cr 9MFY24 : INR 453 cr 9MFY24 : 16.6% 9MFY24 : INR 153 cr 9MFY24 : 14.7% C

INR 2,721

cr 9MFY25 : 19.5% 9MFY25 : INR 251 cr 9MFY25 : 19.5% 15% 35% 288 bps 65% 480 bps 9MFY24 : INR 2,721 cr 9MFY24 : INR 453 cr 9MFY24 : 16.6% 9MFY24 : INR 153 cr 9MFY24 : 14.7% Capacity Beds Avg. Oc

“Operating EBITDA for the period 9M FY25 excludes the ESOP Cost of Rs.”

“While the fixed component of the O&M fee is delineated into depreciation and finance costs as per Ind AS 116, whereas the variable component falls outside the scope of IndAS 116, leading to an incomplete reflection of the standard's impact in EBITDA] The PAT includes an amount of ₹ 85.1 Cr from the interest/gain earned on the investment of sale proceeds from the segregation of GCC vertical and excludes project unity transaction cost of Rs 23.7 Cr.”

“9 Aster India Revenue and Profitability Snapshot – Q3 FY25 10 Revenue from Operations1 Operating EBITDA and Margin1,2 EBITDA and Margin1 (Post Ind As) Adjusted PAT and Margin3 (Post NCI) 17.7% 19.3% 16.4% 18.0% 6.5% 7.7% 1,050 949 202 189 81 168 155 62 15.3% 17.7% Q3FY24 Q3FY25 Q3FY24 Q3FY25 Q3FY24 Q3FY25 Q3FY24 Q3FY25”

“Operating EBITDA for the period 9M FY25 excludes the ESOP Cost of Rs.”

“While the fixed component of the O&M fee is delineated into depreciation and finance costs as per Ind AS 116, whereas the variable component falls outside the scope of IndAS 116, leading to an incomplete reflection of the standard's impact in EBITDA] The PAT includes an amount of ₹ 25.6 Cr from the interest/gain earned on the investment of sale proceeds from the segregation of GCC vertical and excludes project unity transaction cost of Rs 23.7 Cr.”

“(5) Operating EBITDA for the period 9M FY25 excludes the ESOP Cost of Rs.”

“Operating EBITDA for the period 9M FY25 excludes the ESOP Cost of Rs.”

“16 16 Aster India Hospitals: Pipeline Projects Further addition of ~1700 beds, bringing the total bed capacity to ~6,800 by FY27 454 6,830 300 264 FY26 : 564 beds 350 100 FY27 : 904 beds 5,128 159 75 FY25 : 334 beds 9M FY25 Aster Whitefield Block D* Aster Ramesh Ongole* Aster MIMS Kasargod* Aster W&C Hyderabad* Aster CMI** Aster Medcity** Aster Capital Trivandrum FY27 Leased Leased Leased Leased O&M Owned Owned”

“Material Cost % (Ex.Wholesale pharmacy) for Q3 FY25 is 20.8% and Q3 FY24 is 21.5%.”

“Material Cost % (Ex.Wholesale pharmacy) for 9M FY25 is 20.7% and 9M FY24 is 22.3% PAT for the period of Q3 FY25 and 9M FY25 includes an amount of ₹ 25.6 Cr and ₹ 85.1 Cr respectively from the interest/gain earned on the investment of sale proceeds from the segregation of GCC vertical and project unity transaction cost of Rs 23.7 Cr.”

Notes

5

Note

1

Projects Current Status

1

Aster Medcity

1

Aster CMI in India

1

Aster Medcity in India

1

Neuroscience

1

Cardiology

1

Aster CMI

1

Aster DM Foundation

1

Notes

1. Revenue, Operating EBITDA and EBITDA excludes other income. 2. Operating EBITDA for the period 9M FY25 excludes the ESOP Cost of Rs. 7.8 Cr [9M FY24: 3.8 Cr], Movement in fair value of contingent consideration payable of Rs. 8.1 Cr [9M FY24: 1.6 Cr] , Variable O&M fee amounting to Rs.24.2 Cr [9M FY24 : 21.2 Cr]. [Our Operating & Management (O&M) agreements, encompasses both fixed and variable component. While the fixed component of the O&M fee is delineated into depreciation and finance costs as per Ind AS 116, whereas the variable component falls outside the scope of IndAS 116, leading to an incomplete reflection of the standard's impact in EBITDA] The PAT includes an amount of ₹ 85.1 Cr from the interest/gain earned on the investment of sale proceeds from the segregation of GCC vertical and excludes project unity transaction cost of Rs 23.7 Cr. 3. 9 Aster India Revenue and Profitability Snapshot – Q3 FY25 10 Revenue from Operations1 Operating EBITDA and Margin1,2 EBITDA and Margin

Notes

1. Revenue, Operating EBITDA and EBITDA excludes other income 2. Operating EBITDA for the period 9M FY25 excludes the ESOP Cost of Rs. 7.8 Cr [9M FY24: 3.8 Cr], Movement in fair value of contingent consideration payable of Rs. 8.1 Cr [9M FY24: 1.6 Cr] , Variable O&M fee amounting to Rs.24.2 Cr [9M FY24 : 21.2 Cr]. [Our Operating & Management (O&M) agreements, encompasses both fixed and variable component. While the fixed component of the O&M fee is delineated into depreciation and finance costs as per Ind AS 116, whereas the variable component falls outside the scope of IndAS 116, leading to an incomplete reflection of the standard's impact in EBITDA] The PAT includes an amount of ₹ 25.6 Cr from the interest/gain earned on the investment of sale proceeds from the segregation of GCC vertical and excludes project unity transaction cost of Rs 23.7 Cr. 3. 10 Aster India Hospital and other New Business Performance – 9M FY25 % of Revenue Revenue Operating EBITDA(5) Hospitals and Clinics Core

Note

1. The data for hospitals includes numbers for clinics too. 2. Operating EBITDA for the period 9M FY25 excludes the ESOP Cost of Rs. 7.8 Cr [9M FY24: 3.8 Cr], Movement in fair value of contingent consideration payable of Rs. 8.1 Cr [9M FY24: 1.6 Cr] , Variable O&M fee amounting to Rs.24.2 Cr [9M FY24 : 21.2 Cr]. [Our Operating & Management (O&M) agreements, encompasses both fixed andvariable component. While the fixed component of the O&M fee is delineated into depreciation and finance costs as per Ind AS 116, whereas the variable component falls outside the scope of IndAS 116, leading to an incomplete reflection of the standard's impact in EBITDA] 13 Aster India – Hospital Operational Trends No. of Hospitals No. of capacity beds Total patient volumes 19 19 13 12 14 14 4,857 5,128 19 17 3,693 3,757 3,905 3,460 4,867 4,317 (In Mn) 2.7 2.5 3.3 2.9 2.2 2.2 1.8 1.5 9MFY24 9MFY25 FY19 FY20 FY21 FY22 FY23 FY24 9MFY24 9MFY25 FY19 FY20 FY21 FY22 FY23 FY24 9MFY24 9MFY25 FY19 FY20 FY21* FY22 FY2

Projects Current Status

*Aster Whitefield block D, Aster Ramesh Ongole, Aster Kasargod, Aster W&C Hyderabad and Aster Capital are in Construction phase ** Aster CMI and Aster Medcity (PMR block) are in design phase. 17 17 Our strategic priorities towards driving future growth and improvement in profitability y g e t a r t S h t w o r G Capital Investment Operational Efficiency Cost Optimisation Initiatives Continuity of Care Technology & Digital A B C D E Focus Areas ✓ Investing prudently in both brownfield (expanding existing units) and greenfield projects across clusters and opportunistically exploring inorganic opportunities ✓ Focusing more on niche specialties to drive better ARPOB ✓ Optimizing existing facilities – Payor mix & high-end procedures ✓ To enhance efficiency and lower operational expenses, thereby improving EBITDA margins ✓ Creation of ecosystem by gradually establishing labs and pharmacies ✓ Leveraging technology & digital medium for superior patient outcomes and reach 18 Aster India Financi

Aster Medcity

All India 1 Aster CMI Hospital: All India 4 Aster Medcity: India Best Multispecialty Aster Medcity : All India Best Multispeciality Hospital Aster CMI : All India Best Multispecialty Hospital Aster Medcity : South Best Multispeciality Hospital Aster CMI : South Best Multispecialty Hospital 2 6 1 2 Best Hospital Chain of the Year Best Hospital Chain & Healthcare Brand of the Year The Worlds Best Hospitals 2024

Aster Medcity in India

34 4-star Global Hospital Rating 4-star Global Hospital Rating 3 6 4 4 Aster CMI : India Best Multispecialty Aster Medcity : India Aster CMI : India Oncology Aster CMI : Bengaluru Aster Medcity : Kochi Best Multispecialty Aster Medcity : India